Cardiovascular Disease Reduction in the Outpatient Kidney Transplant Clinic

American Journal of Transplantation

Volumn 3, Issue 11, 2003, Pages 1393-1399

  Kiberd, Bryce ^a   Keough Ryan, Tammy ^a   Panek, Roman ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Framingham risk; Hyperlipidemia; Hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; PREDNISONE; RAPAMYCIN; STATINE DERIVATIVE; TACROLIMUS;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONFIDENCE INTERVAL; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT DEPARTMENT; PHYSICIAN; PREDICTION; PRESCRIPTION; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TREATMENT CONTRAINDICATION;

ADULT; AMBULATORY CARE FACILITIES; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERLIPIDEMIAS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TIME FACTORS;

EID: 0142059117     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.2003.00240.x     Document Type: Article

References (36)

1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
2. US Renal Data System, USRDS 2000 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000.
3. US Vital and Health Statistics. Hyattsville, MD: National Center for Health Statistics; 2000.
4. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
5. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72 (Suppl.): S5-S8.
6. Locatelli F, Marcelli D, Conte F et al. for the Registro Lombardo Dialisi e Trapianto. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15 (Suppl. 5): 69-80.
7. Kiberd BA. Cardiovascular risk reduction in renal transplantation. Minerva Urol Nefrol 2002; 54: 51-63.
8. Levey A. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis 1998; 32 (Suppl. 3): S51-S13.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
10. MDRD Study Group. Predicting GFR from serum creatinine in the MDRD study: a correction. J Am Soc Nephrol 1928; 9: 153A.
11. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S5.
12. Bostom AD, Brown RS, Jr, Chavers BM et al. Prevention of posttransplant cardiovascular disease - report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491-500.
13. Kasiske BL. Hyperlipidemia in patients with chronic: renal disease. Am J Kidney Dis 1998; 32 (Suppl. 3): S142-S156.
14. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34.
15. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
16. Joint National Committee. The Sixth Report of the Joint National Committee on the prevention, detection evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
17. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ 2001; 323: 75-81.
18. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
19. Hingorani AD, Vallance P. A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 1999; 318: 101-105.
20. Beck JR, Kassirer JP, Pauker SG, Gottlieb JE, Klein K. A convenient approximation of life expectancy. Am J Med 1982; 73: 883-897.
21. Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs 2002; 62: 2333-2347.
22. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 9: 1735-1743.
23. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354.
24. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 2003; 14: 462-468.
25. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol 2002; 13: 1084-1090.
26. Shiplak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137: 555-562.
27. Goldsmith DJA, Covic A. Coronary artery disease in uremia: etiology, diagnosis and therapy. Kidney Int 2001; 60: 2059-2078.
28. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. Transplantation 2002; 74: 1377-1381.
29. Kiberd BA, West KA. Targeting cardiovascular risk in renal transplantation. Transplant Proc 2001; 33: 1117-1118.
30. Collaborative Group of the Primary Prevention Project. Low dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357: 89-95.
31. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988; 296: 320-331.
32. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 707-709.
33. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S33.
34. Law M, Tang JL. An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 1995; 155: 1933-1941.
35. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation (Cochrane Review). Cochrane Database Syst Rev 2001; 3: CD000146.
36. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2000; 4: CD000031.